Table 3.
Cost-effectiveness | Intervention Classification ≠ | |||
---|---|---|---|---|
Cost-saving † | Food Intake | Physical Activity | Food Intake & Physical Activity | |
School-based education programme to reduce sugar-sweetened drink consumption [38] Reduction of advertising of unhealthy food and beverages to children [43] Front-of-pack traffic light nutrition labelling [47] Unhealthy food and beverage tax (10%) [47] |
School (curriculum)-based education programme to reduce television viewing [38] Multi-faceted school (curriculum)-based programme including nutrition and physical activity [38] Family-based GP programme targeted at obese children [38] Multi-faceted targeted school-based programme for overweight and obese children [38] |
|||
Cost-effective ‡ (ICER ≤ $50,000/DALY) |
Orlistat (obese adolescents µ) [38] Laparoscopic adjustable gastric for obese adults (BMI > 35) β [42] Laparoscopic adjustable gastric for obese adolescents [40] Low-fat diet for adults BMI > 25 [41] |
Family-based GP programme targeted at overweight and moderately obese children [45] Multi-faceted school (curriculum)-based programme without an active physical activity component (this intervention included education on physical activity) [38] Diet and exercise for adults BMI > 25 [41] |
||
Not cost-effective ∫ (ICER > $50,000/DALY) |
Sibutramine (obese adults) * [48] Orlistat (obese adults) [48] |
Walking school bus [44] TravelSMART schools α [46] Active after schools communities program [49] |
Lighten up to a healthy lifestyle weight-loss programme for adults π [39] Weight Watchers [39] |
Notes: ≠ The costs included in the economic analyses are the costs of intervention implementation, delivery and the healthcare ramification costs or cost offsets. Productivity costs have not been included. † Interventions with net cost-effectiveness results (includes cost offsets) which are cost-saving. ‡ Interventions with incremental cost-effectiveness ratios (ICER) below the threshold value of AUD 50,000 per DALY averted. ∫ Interventions with ICER above the threshold value of AUD 50,000 per DALY averted. µ Orlistat is restricted for use in adults only in Australia. β Results were cost-saving when the intervention was targeted at obese adults with BMI > 40. * Withdrawn from Australian in 2010. α School and community based intervention aimed to increase active transport. π Although not restricted/targeted, the majority of participants were overweight or obese.